يعرض 1 - 4 نتائج من 4 نتيجة بحث عن '"Jan Romero"', وقت الاستعلام: 1.35s تنقيح النتائج
  1. 1
    Discovery of Brigatinib (AP26113), a Phosphine Oxide-Containing, Potent, Orally Active Inhibitor of Anaplastic Lymphoma Kinase

    المؤلفون: Shuangying Liu, Xiaotian Zhu, Angela Toms, Yongjin Xu, David C. Dalgarno, Rory Dodd, Lois Parillon, Yihan Wang, Scott Wardwell, Tim Clackson, Jiwei Qi, Anna Kohlmann, Yaoyu Ning, Hyun Gyung Jang, Xiaohui Lu, Lisi Cai, Qurish K. Mohemmad, Rongsong Xu, Dong Zou, Sen Zhang, William C. Shakespeare, Timothy A. Dwight, Narayana I. Narasimhan, Qihong Xu, Rana Anjum, Lauren Moran, Tianjun Zhou, Frank Wang, Mathew Thomas, Wei-Sheng Huang, Jeffrey A. Keats, Feng Li, Jan Romero, Victor M. Rivera

    المصدر: Journal of medicinal chemistry. 59(10)

    مصطلحات موضوعية: 0301 basic medicine, Lung Neoplasms, Brigatinib, Cell Survival, Phosphines, Molecular Conformation, Administration, Oral, Antineoplastic Agents, Mice, SCID, Bioinformatics, 03 medical and health sciences, Mice, Structure-Activity Relationship, 0302 clinical medicine, Organophosphorus Compounds, hemic and lymphatic diseases, Carcinoma, Non-Small-Cell Lung, Cell Line, Tumor, Drug Discovery, medicine, Anaplastic lymphoma kinase, Animals, Humans, Anaplastic Lymphoma Kinase, Lung cancer, Protein Kinase Inhibitors, ADME, Cell Proliferation, chemistry.chemical_classification, Dose-Response Relationship, Drug, Kinase, Chemistry, Receptor Protein-Tyrosine Kinases, Neoplasms, Experimental, medicine.disease, Lymphoma, Rats, 030104 developmental biology, Enzyme, Pyrimidines, Protein kinase domain, 030220 oncology & carcinogenesis, Cancer research, Molecular Medicine, Female, Drug Screening Assays, Antitumor

    URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::625d183379f1d6b062d2872fda27b944
    https://pubmed.ncbi.nlm.nih.gov/27144831

    Find this issue from the American Chemical Society
    أضف إلى المفضلة
  2. 2
    Discovery of 5-(arenethynyl) hetero-monocyclic derivatives as potent inhibitors of BCR–ABL including the T315I gatekeeper mutant

    المؤلفون: Xiaotian Zhu, Dong Zou, Chester A. Metcalf, Raji Sundaramoorthi, Frank Wang, Feng Li, Jan Romero, John Iuliucci, Lois Commodore, Shuangying Liu, Wei-Sheng Huang, Lisi Cai, Qihong Xu, Jeff Keats, Tim Clackson, David C. Dalgarno, Joseph Snodgrass, Jiwei Qi, Yihan Wang, Victor M. Rivera, Mathew Thomas, Ingrid Chen, Tianjun Zhou, Yaoyu Ning, David Wen, Tomi K. Sawyer, Karin Russian, William C. Shakespeare, Marc I Broudy, Scott Wardwell

    المصدر: Bioorganic & Medicinal Chemistry Letters. 21:3743-3748

    مصطلحات موضوعية: Models, Molecular, medicine.drug_class, Stereochemistry, Clinical Biochemistry, Mutant, Fusion Proteins, bcr-abl, Administration, Oral, Pharmaceutical Science, Carboxamide, Biochemistry, Mice, Structure-Activity Relationship, chemistry.chemical_compound, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, hemic and lymphatic diseases, Drug Discovery, medicine, Animals, Molecular Biology, Aniline Compounds, Molecular Structure, biology, Chemistry, Organic Chemistry, Ponatinib, Biological activity, medicine.disease, In vitro, Rats, Disease Models, Animal, Cyclization, Enzyme inhibitor, Alkynes, Mutation, biology.protein, Molecular Medicine, Linker, Toluene, Chronic myelogenous leukemia

    URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::66a38549836ca328c6bb343c0b0ec0da
    https://doi.org/10.1016/j.bmcl.2011.04.060

    View record from ScienceDirect
    أضف إلى المفضلة
  3. 3
    Discovery of 3-[2-(Imidazo[1,2-b]pyridazin-3-yl)ethynyl]-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide (AP24534), a Potent, Orally Active Pan-Inhibitor of Breakpoint Cluster Region-Abelson (BCR-ABL) Kinase Including the T315I Gatekeeper Mutant

    المؤلفون: Yaoyu Ning, Chester A. Metcalf, Lois Commodore, Jan Romero, Scott Wardwell, Tomi K. Sawyer, Yihan Wang, Qurish K. Mohemmad, Scott Paul Lentini, Ingrid Chen, Victor M. Rivera, Karin Russian, Geetha Banda, Sasmita Das, Narayana I. Narasimhan, Xiaotian Zhu, Raji Sundaramoorthi, Lisi Cai, Tianjun Zhou, Jeff Keats, Frank Wang, Tim Clackson, Qihong Xu, Jiwei Qi, David Wen, Joseph Snodgrass, Shuangying Liu, William C. Shakespeare, R. Mathew Thomas, Marc I Broudy, John Iuliucci, Wei-Sheng Huang, David C. Dalgarno, Dong Zou

    المصدر: Journal of Medicinal Chemistry. 53:4701-4719

    مصطلحات موضوعية: Models, Molecular, Mutant, Fusion Proteins, bcr-abl, Administration, Oral, Antineoplastic Agents, Mice, SCID, Pharmacology, Crystallography, X-Ray, Mice, chemistry.chemical_compound, Cell Line, Tumor, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, hemic and lymphatic diseases, Drug Discovery, medicine, Animals, Kinase activity, Benzamide, Protein Kinase Inhibitors, ADME, Kinase, Chemistry, Imidazoles, breakpoint cluster region, Myeloid leukemia, medicine.disease, Rats, Pyridazines, Leukemia, Blood-Brain Barrier, Mutation, Molecular Medicine, Drug Screening Assays, Antitumor

    URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::757a483ca43d6a44106283733dc26b6a
    https://doi.org/10.1021/jm100395q

    Find this issue from the American Chemical Society
    أضف إلى المفضلة
  4. 4
    دورية أكاديمية
    Discovery of 3-[2-(Imidazo[1,2-b]pyridazin-3-yl)ethynyl]-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide (AP24534), a Potent, Orally Active Pan-Inhibitor of Breakpoint Cluster Region-Abelson (BCR-ABL) Kinase Including...

    المؤلفون: Wei-Sheng Huang, Chester A. Metcalf, Raji Sundaramoorthi, Yihan Wang, Dong Zou, R. Mathew Thomas, Xiaotian Zhu, Lisi Cai, David Wen, Shuangying Liu, Jan Romero, Jiwei Qi, Ingrid Chen, Geetha Banda, Scott P. Lentini, Sasmita Das, Qihong Xu, Jeff Keats, Frank Wang, Scott Wardwell

    المصدر: Journal of Medicinal Chemistry; Jun2010, Vol. 53 Issue 12, p4701-4719, 19p

    Find this issue from the American Chemical Society
    أضف إلى المفضلة
أدوات البحث: أحصل على تغذية RSS – أرسل هذا البحث بالبريد الإلكتروني – حفظ البحث – جدول التنبيهات: لا شيء